SHANGHAI, March 31, 2026 /PRNewswire/ -- 31 March 2026, Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics" hereafter, HKEX code: 02256) announced that its independently developed, highly selective, oral small-molecule FGFR4 inhibitor irpagratinib (ABSK-011), has been granted Orphan...
Hence then, the article about abbisko therapeutics fgfr4 inhibitor irpagratinib granted orphan drug designation by ema for hepatocellular carcinoma was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Abbisko Therapeutics' FGFR4 Inhibitor Irpagratinib Granted Orphan Drug Designation by EMA for Hepatocellular Carcinoma )
Also on site :
- Hezbollah Denies Bahraini Interior Ministry& 039;s Baseless Allegations
- This 30-Year-Old Start to a Book Series Is Named the Best Epic Fantasy on Goodreads
- New Study Claims That Traveling Regularly Can Actually Help You Live Longer